A medical specialist holds a vial of Sputnik V vaccine against the coronavirus in a department store in Moscow. Picture credit: ( Reuters )
HYDERABAD: Even as India is gearing up to roll out Russian Covid-19 vaccine Sputnik V next week, a group of international experts has raised serious questions about the data discrepancies and substandard reporting of interim data of the vaccine’s phase 3 trials. Raising the red flag on discrepancies in the trials data, changes in the trial protocols, quality and accuracy of data as well as a lack of transparency, they said: “Restricted access to data hampers trust in research. Access to data underpinning study findings is imperative to check and confirm the findings claimed.”